BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labgaa I, Tabrizian P, Titano J, Kim E, Thung SN, Florman S, Schwartz M, Melloul E. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB 2019;21:1497-504. [DOI: 10.1016/j.hpb.2019.03.360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Qin JM. Conversion therapy for primary liver cancer: Indications and selective strategies. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 501-510 [DOI: 10.11569/wcjd.v29.i10.501] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Johnson GE, Padia SA. Yttrium-90 Radiation Segmentectomy. Semin Intervent Radiol 2020;37:537-42. [PMID: 33328710 DOI: 10.1055/s-0040-1720953] [Reference Citation Analysis]
3 Serenari M, Ratti F, Zanello M, Guglielmo N, Mocchegiani F, Di Benedetto F, Nardo B, Mazzaferro V, Cillo U, Massani M, Colledan M, Dalla Valle R, Cescon M, Vivarelli M, Colasanti M, Ettorre GM, Aldrighetti L, Jovine E. Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. J Laparoendosc Adv Surg Tech A 2020;30:1082-9. [PMID: 32907480 DOI: 10.1089/lap.2020.0563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Sun HC, Zhu XD. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Front Oncol 2021;11:772195. [PMID: 34869008 DOI: 10.3389/fonc.2021.772195] [Reference Citation Analysis]
5 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
6 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
7 Kim Y, Lee HA, Lee JS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Seo YS, Kim SU. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. Cancer Invest 2021;39:274-83. [PMID: 33356630 DOI: 10.1080/07357907.2020.1870126] [Reference Citation Analysis]
8 Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol 2021;28:965-77. [PMID: 33617513 DOI: 10.3390/curroncol28010095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
10 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
11 Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sivananthan G, Tabori NE. Principles of Radioembolization. Semin Intervent Radiol 2021;38:393-6. [PMID: 34629704 DOI: 10.1055/s-0041-1735606] [Reference Citation Analysis]
13 Noda C, Williams GA, Foltz G, Kim H, Sanford DE, Hammill CW, Fields RC. The safety of hepatectomy after transarterial radioembolization: Single institution experience and review of the literature. J Surg Oncol 2020;122:1114-21. [PMID: 32662066 DOI: 10.1002/jso.26115] [Reference Citation Analysis]
14 Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2021:S1365-182X(21)01592-6. [PMID: 34607769 DOI: 10.1016/j.hpb.2021.08.948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
16 Decoteau MA, Steuterman S, Kurian SM, Case J, Lewis PR, Fisher JS, Schaffer RL, Marsh CL. Mitigation of radiation exposure during surgical hepatectomy after yttrium-90 radioembolization. J Radiol Prot 2021;41. [PMID: 34107455 DOI: 10.1088/1361-6498/ac09c0] [Reference Citation Analysis]